Navigation Links
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Date:9/6/2011

TARRYTOWN, N.Y., Sept. 6, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Joseph J. LaRosa has been appointed Senior Vice President, General Counsel and Secretary.  Mr. LaRosa will be responsible for overseeing all of the Company's legal affairs, including general corporate legal matters, intellectual property and corporate compliance, and will report to Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer.

"We are extremely pleased to have recruited a seasoned corporate attorney with deep senior-level pharmaceutical experience to lead this important function," said Dr. Schleifer.  "Joe's track record managing a variety of key legal functions at Schering-Plough and Nycomed will be directly relevant as Regeneron, which now employs more than 1,600 people, continues to build its product portfolio and the capabilities of a fully integrated pharmaceutical company."

Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team.  He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc.  Most recently Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed US Inc.

"I am excited to join the Regeneron senior management team at a time when the company is emerging as one of the best-positioned biotechnology companies," said Mr. LaRosa, who holds undergraduate and J.D. degrees from New York University.  "Regeneron is known for outstanding science and innovative collaborations with leading pharmaceutical companies, and in recent years it has also demonstrated its abilities in clinical development, manufacturing, and commercialization of new biotechnology-ba
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regeneron Announces Review of Biologics License Application for EYLEAâ„¢ (aflibercept injection) Extended by Three Months by FDA
2. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
3. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
4. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
5. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Genprex Announces New Branding
8. BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026
9. BioInformatics LLC Announces the Life Science Industry Awards on November 15, 2011 in Washington, DC
10. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
11. BD Biosciences Announces Winners of Research Grant Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... available in German . ... Mnchen (TUM) have demonstrated a new kind of building ... future computer chips could be based on three-dimensional arrangements ... enabling technology of the semiconductor industry CMOS fabrication ... researchers and collaborators at the University of Notre Dame ...
(Date:9/30/2014)... Sept. 30, 2014 Nematicide is a ... Nematodes are microscopic parasitic roundworms, found in massive ... other plants and animals. Nematicides have tended to ... properties promoting migration through the soil. A single ... plant-parasitic nematodes. With more than 10,000 species classified, ...
(Date:9/30/2014)... CORD:USE Cord Blood Bank – www.corduse.com ... entered into an Equity and Exclusive Services Agreement with ... of patented technologies for the isolation of human cord ... is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that the ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... Principle Reached to Terminate Marketing Agreement with Triax ... on Most Favorable Terms, NAPA, Calif., May 15 ... company engaged in the development,of technologies that target the ... quarter ended March 31, 2008 and an agreement in,principle ...
... May 15 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) ... & Renshaw 5th Annual Global Healthcare Conference on,May 19, ... and at the 2008 UBS,Global Generic and Specialty Pharmaceuticals ... time (5:00 a.m. EDT). The presentations will,be web cast ...
... Mass., May 15 Hologic, Inc. (Nasdaq:,HOLX) today ... be,presenting at the Citigroup Investment Research Global Healthcare,Conference ... the Hilton Hotel in New York,NY., Interested ... audio webcast of,Hologic,s investor presentation on Thursday, May ...
Cached Biology Technology:Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... runoff in Hawaii is causing tumors in endangered sea ... published Tuesday in the peer-reviewed open-access journal PeerJ ... in algae that the turtles eat, promoting the formation ... organs. , Scientists at Duke University, the University of ... conducted the study to better understand the causes ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... activity resource, a personal assistant - computers are ubiquitous. ... lot to be desired: they rapidly become obsolete, typically ... components that are difficult to recycle. Moreover, they consume ... release of CO2 into the atmosphere. Employees at ...
... a vital element not only for plants but also ... have been faced with a growing shortage of this ... been steadily increasing. It is therefore high time to ... task, because phosphorus cannot be replaced by any other ...
... a biological marker that may help to identify ... rapid-acting antidepressant. The brain signal, detectable by noninvasive ... mechanism, which are vital for drug development, say ... is among the latest of several such markers, ...
Cached Biology News:Eco-computer with a natural wood look 2Using wastewater as fertilizer 2Using wastewater as fertilizer 3Brain signal IDs responders to fast-acting antidepressant 2Brain signal IDs responders to fast-acting antidepressant 3Brain signal IDs responders to fast-acting antidepressant 4Brain signal IDs responders to fast-acting antidepressant 5Brain signal IDs responders to fast-acting antidepressant 6
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Biology Products: